MMI Builds Global Momentum with Multiple Distribution Agreements and Regulatory Approvals
2024年7月9日 - 8:30PM
ビジネスワイヤ(英語)
Expansion includes fastest-growing market for
microsurgical procedures and opportunity for considerable
advancement, improved patient treatment options
MMI (Medical Microinstruments, Inc.), a robotics company
dedicated to increasing treatment options and improving clinical
outcomes for patients with complex conditions, today announced
milestones across two continents that increase the global reach of
the Symani® Surgical System. The company announced:
- It reached an exclusive distribution agreement with Gunze
Medical Limited, a leading developer and manufacturer of medical
devices in Japan. The agreement signals a step toward
commercializing Symani across Japan, upon regulatory approval, and
will eventually enable hospitals there to expand their open
surgical programs to include microsurgery and supermicrosurgery
procedures.
- The Symani Surgical System has now received regulatory
approvals in 35 countries around the world, most recently securing
approvals in Hong Kong, Malaysia, New Zealand and Taiwan. They mark
Symani’s latest regulatory milestones following the U.S. Food and
Drug Administration authorizing the system for commercial use in
April.
- It has expanded commercialization efforts in Europe by
partnering with the Synektik Group, a leading integrator of
innovative medical solutions that covers six countries across
Eastern Europe. The agreement marks the next stage in bolstering
Synektik’s standing as a top distributor of robotic medical systems
in the region.
“The demand for innovative, less invasive, highly precise
surgical options is increasing around the world, particularly in
Asia, where microsurgery and reconstructive surgery both have long
histories,” said Mark Toland, CEO of MMI. “Our recent regulatory
approvals in multiple countries, and growing relationships with
distributors in key markets, have enabled us to accelerate our
timeline for global expansion. Each new milestone represents
another step toward expanding patient access to highly advanced
microsurgical capabilities around the world.”
The Symani Surgical System uniquely addresses the scale and
complexities of microsurgery and supermicrosurgery, such as the
anastomosis and suturing of small anatomical structures like blood
and lymphatic vessels, during open surgical procedures. By allowing
surgeons to replicate the natural movements of the human hand at
the micro scale, it can help restore quality of life for more
patients, accelerate the number of surgeons able to push the
boundaries of complex procedures for delicate anatomy, and enable
hospitals to expand their open surgical programs.
“Our partnership with MMI will facilitate the Symani Surgical
System’s expansion into Japan,” said Shojiro Matsuda, President of
Gunze Medical Limited. “We are deeply committed to expanding
patient access to robotic-assisted microsurgery and believe
Symani’s proven clinical success will complement our relationships
with care provider organizations with expertise in plastic and
reconstructive surgery.”
Asia-Pacific represents the fastest growing microsurgery market
in the world, and Taiwan specifically is a hub of microsurgical
innovation that attracts surgeons from around the globe. MMI has
already signed a distributor agreement in the country to support
its regulatory approval there and details are being finalized on
the heels of the authorization.
“MMI’s mission to expand patient access to highly specialized
microsurgical options perfectly aligns with our own as we help to
further enable robotic capabilities across Poland and Eastern
Europe,” said Cezary Kozanecki, founder and CEO of Synektik.
“Symani has introduced a new level of capability and enabled
surgeons to perform exceptionally precise procedures that include
lymphedema repair, head and neck cancer-related reconstruction, and
autologous breast reconstruction. Our health system partners have
already expressed significant interest in expanding their open
surgery capabilities to include procedures they haven’t been able
to previously perform.”
To learn more about MMI and the Symani Surgical System, visit
MMI’s website here: https://mmimicro.com.
About MMI
MMI (Medical Microinstruments, Inc.) is on a mission to advance
robotic technology that pushes the limits of soft tissue open
surgery and opens new opportunities for surgeons to restore quality
of life for more patients with complex conditions. The company was
founded in 2015 near Pisa, Italy, and its proprietary Symani®
Surgical System combines the world’s smallest wristed
microinstruments with tremor-reducing and motion-scaling
technologies to address significant unmet patient needs across the
globe. This first-of-its-kind surgical robotic platform for open,
soft tissue micro-level surgery can help address microvascular
repair and lymphatic repair. In Europe and APAC, it also addresses
peripheral nerve repair. The Symani System is authorized for use in
the U.S. by the FDA and is a CE Marked medical device in Europe.
MMI is backed by global investors including Fidelity Management
& Research Company, Andera Partners, BioStar, Deerfield
Management, Fountain Healthcare Partners, Panakès Partners, RA
Capital, Sambatech, and Wellington Partners.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240709821670/en/
Media: Dan Ventresca Matter Health for MMI MMI@matternow.com
Investor Relations: Lisa Croke Lisa.Croke@mmimicro.com